Treatment of Bone Manifestations of Disseminated MAC
Bone manifestations of disseminated MAC require aggressive surgical debridement combined with prolonged multidrug antimicrobial therapy consisting of a macrolide (clarithromycin or azithromycin), ethambutol, and rifampin/rifabutin for at least 12 months beyond culture conversion, with treatment duration often extending 18-24 months for bone involvement.
Surgical Management
The cornerstone of treating MAC bone disease is thorough surgical intervention 1:
- Perform complete surgical debridement of all infected bone and soft tissue
- Send multiple tissue samples (as much as safely possible) specifically for mycobacterial cultures with explicit instructions to hold cultures for 6 weeks given variable growth rates
- For localized bone infection without joint involvement: debridement with local implant removal if present
- For deep infections with articular involvement: remove all fixation and graft materials plus extensive bony debridement
- If prosthetic joint is involved: two-stage revision is the benchmark approach with delayed reimplantation after 6 months of antimicrobial therapy 1
Critical pitfall: ESR/CRP can be negative in initial workup—do not exclude indolent infection based on normal inflammatory markers 1.
Antimicrobial Therapy
The medical regimen should mirror treatment for disseminated MAC disease 2:
Standard Regimen
- Clarithromycin or azithromycin (macrolide is essential as first agent)
- Ethambutol 15 mg/kg/day (most rational second agent)
- Rifampin or rifabutin (rifampin 10 mg/kg/day, maximum 600 mg)
- Consider adding parenteral amikacin for extensive disease 2, 3
Treatment Duration
- Minimum 12 months beyond culture conversion for pulmonary MAC 2
- For bone involvement: 18-24 months total duration based on case reports of successful treatment 4
- Deep bone and joint infections require markedly longer treatment durations than soft tissue infections 1
Monitoring Strategy
- Confirm eradication before any reimplantation with joint aspirations 1
- Close clinical monitoring with frequent cultures throughout therapy
- New lesions during active therapy after initial improvement may represent immunologic response to dying mycobacteria rather than treatment failure 1
Multidisciplinary Approach
Mandatory consultation with infectious disease specialist and pharmacy for:
- Drug-drug interaction management (especially with antiretrovirals if HIV-positive)
- Monitoring for drug toxicity with prolonged therapy
- Adjusting regimen based on susceptibility testing 1
Key Clinical Considerations
Resistance patterns: Clarithromycin resistance is rare (0.5%) but catastrophic—always obtain susceptibilities 5. If macrolide resistance is documented (A2059G mutation in 23S rRNA), substitute moxifloxacin or use alternative fluoroquinolone-based regimen 2.
Recurrence risk: Remains high even with appropriate therapy—long-term follow-up is essential 1. Approximately 50% of treatment-refractory patients eventually require retreatment 6.
Single-stage revision and chronic suppressive antibiotics can be attempted but have lower success rates due to poorly tolerated prolonged antibiotic regimens 1.